

**Headquarters**

Thousand Oaks, California

Staff

Approximately
24,000 worldwide

Stock Listing

NASDAQ: AMGN

Chairman and CEO

Robert A. Bradway

2021 Financial Highlights**Total revenue**

\$26.0 billion

Product sales

\$24.3 billion

R&D expense

\$4.8 billion

Address/Phone

One Amgen Center Drive
Thousand Oaks, CA 91320-1799

Main

805.447.1000

Investors

805.447.1060

About Amgen

Our Mission: To Serve Patients

Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing, and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.

Our belief—and the core of our strategy—is that innovative, highly differentiated medicines provide large clinical benefits in addressing serious diseases. And we believe these medicines not only help patients, but also help reduce the social and economic burden of disease in society.

Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology innovator since 1980, Amgen has grown to be one of the world's leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.

Products

Aimovig® (erenumab-aooe)
AMGEVITA™ (adalimumab)
AMJEVITA™ (adalimumab-atto)
Aranesp® (darbepoetin alfa)
AVSOLA™ (infliximab-axxq)
BLINCYTO® (blinatumomab)
Corlanor® (ivabradine)
Enbrel® (etanercept)
EPOGEN® (epoetin alfa)
EVENTY® (romosozumab-aqqg)
IMLYGIC® (talimogene laherparepvec)
KANJINTI® (trastuzumab-anns)
KYPROLIS® (carfilzomib)
LUMAKRAS™ (sotorasib)
MVASI® (bevacizumab-awwb)
Neulasta® (pegfilgrastim)
NEUPOGEN® (filgrastim)
Nplate® (romiplostim)
Otezla® (apremilast)
Parsabiv® (etelcalcetide)
Prolia® (denosumab)
Repatha® (evolocumab)
RIABNI™ (rituximab-arrx)
Sensipar®/Mimpara® (cinacalcet)
TAVNEOS® (avacopan)
TEZSPIRE® (tezepelumab-ekko)
Vectibix® (panitumumab)
XGEVA® (denosumab)

Aimovig® is developed in collaboration with Novartis. For information about our pipeline and therapies, visit www.amgen.com.

INNOVATION MEDICINES

We have a presence in approximately 100 countries and regions worldwide and our innovative medicines have reached millions of people in the fight against serious illnesses. We focus on six therapeutic areas: cardiovascular disease, oncology, bone health, neuroscience, nephrology, and inflammation. Our medicines typically address diseases for which there are limited treatment alternatives, or they are medicines that provide a viable option to what is otherwise available.

TRANSFORMATIVE RESEARCH

Understanding the fundamental biological mechanisms of disease is a defining feature of Amgen's discovery research efforts—and a major contributor to the development of Amgen's deep and broad pipeline of potential new medicines. Amgen's "biology first" approach permits its scientists to first explore the complex molecular pathways of disease before determining what type of medicine, or modality, is most likely to deliver optimal efficacy and safety. With the advances in human genetics, Amgen continues to shed new light on the molecular roots of disease. Amgen subsidiary deCODE Genetics, a global leader in human genetics, is a powerful differentiator, greatly improving how we identify and validate human disease targets.

WORLD-CLASS BIOMANUFACTURING

The treatment of millions of seriously ill patients worldwide depends on the safe and reliable production of biologic medicines, which are administered by injection or intravenously. A worldwide leader in biologics manufacturing, Amgen has an outstanding track record of reliably delivering high-quality medicines to patients who need them. Significant skill, experience, vigilance and commitment are critical to help ensure the quality of each and every dose of the biologic medicines we make. At Amgen, robust quality control and a reliable supply of medicines for patients are every bit as important as scientific innovation.

OUR HERITAGE

Building on advances in recombinant DNA and molecular biology, Amgen is counted among the early pioneers of biotechnology. Since 1980, Amgen scientists have been at work developing novel therapies for patients with serious illnesses. Our scientists have characterized key biologic processes that led to the development of innovative, first-in-class therapies. We have helped shape the scientific world's understanding of certain disease processes, and we have engineered new types of therapeutic platforms. As a company, we could not have accomplished all of this were it not for our deep commitment to building a culture that embraces science and innovation—a culture that continues to shape who we are today.



THE AMGEN FOUNDATION

The Amgen Foundation is inspiring the next generation of scientists and future problem solvers, providing best-in-class science education at no cost to students. To date, the Foundation has donated over \$375 million to local, regional, and international non-profit organizations that impact society in inspiring and innovative ways. The Amgen Foundation brings the excitement of discovery to the scientists of tomorrow through its signature programs, including LabXchange, Amgen Scholars, and the Amgen Biotech Experience. For more information, visit www.AmgenFoundation.org.

REACHING PATIENTS WORLDWIDE

Amgen medicines help patients worldwide with facilities or subsidiaries in the following locations:

In the United States

California (South San Francisco, Thousand Oaks), Florida (Tampa), Kentucky (Louisville), Massachusetts (Cambridge, Woburn), Puerto Rico (Juncos), Rhode Island (West Greenwich), Washington, D.C.

Outside the United States

- Algeria
- Argentina
- Australia
- Austria
- Belgium
- Brazil
- Bulgaria
- Canada
- China
- Colombia
- Croatia
- Czech Republic
- Denmark
- Egypt
- Estonia
- Finland
- France
- Germany
- Greece
- Hong Kong
- Hungary
- Iceland
- India
- Ireland
- Israel
- Italy
- Japan
- Jordan
- Korea
- Latvia
- Lebanon
- Lithuania
- Luxembourg
- Mexico
- Morocco
- Netherlands
- New Zealand
- Norway
- Poland
- Portugal
- Romania
- Russia
- Saudi Arabia
- Singapore
- Slovakia
- Slovenia
- South Africa
- Spain
- Sweden
- Switzerland
- Taiwan
- Thailand
- Turkiye
- United Arab Emirates
- United Kingdom



Facebook

@amgenbiotech

Instagram

@amgenbiotech

LinkedIn

/amgen

Twitter

@amgen

YouTube

@amgen

Investor Information

This fact sheet is a summary of more detailed disclosure that can be found in Amgen's filings with the U.S. Securities and Exchange Commission and its press releases. This fact sheet contains forward-looking statements that involve significant risks and uncertainties, discussion of which can be found in Amgen's most recent Forms 10-K, 10-Q, and 8-K and on <http://investors.amgen.com>. The information in this fact sheet is given as of the date below, and Amgen does not undertake any obligation to update any information in this document.

AMGEN